Bibliothèque de L'IMIST/CNRST

Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: BNP Molecular Forms and Processing by the Cardiac Serine Protease Corin; 1. Introduction; 2. BNP Molecular Forms: Implications for Biomarker and Therapeutic Use in Cardiovascular Disease; 2.1. Background; 2.2. BNP signal peptide; 2.3. NT-proBNP1-76 and BNP1-32; 2.4. Degradation products: BNP3-32, BNP5-32, and smaller peptides; 2.5. ProBNP1-108; 3. BNP Paradox in Heart Failure; 4. BNP Processing and Propeptide Convertases; 5. Cardiac Serine Protease, Corin; 5.1. Expression and function.

5.1.1. General information under physiologic conditions5.1.2. Animal models; 5.1.3. Human corin single-nucleotide polymorphism; 5.1.4. Human disease states and gender differences; 5.2. Other topics; 5.2.1. BNP processing in the circulation; 5.2.2. Role of glycosylation on BNP molecular forms and processing; 6. Clinical Implication and Future Directions; Acknowledgments; References; Chapter Two: Current Applications of Cardiac Troponin T for the Diagnosis of Myocardial Damage; 1. Introduction; 2. Biology and Function; 2.1. History; 2.2. Cardiac myofibrillar apparatus.

2.3. Troponin complex function2.4. Troponin isoforms; 2.5. Myocardial ischemia and necrosis; 3. Troponin Assays; 3.1. History; 3.2. Principle of test; 3.3. Cutoffs and sensitivity; 3.4. Preanalytic factors; 3.5. Assay standardization; 4. TnT Clinical Applications; 4.1. Myocardial necrosis; 4.1.1. AMI with ST-segment elevation; 4.1.2. Acute coronary syndromes without persistent STEMIs (unstable angina and non-ST-segment myocardial infarction); 4.1.3. Differential diagnosis of increased troponin; 4.1.4. Practical recommendations for use; 4.2. Pulmonary artery embolism.

4.3. Pulmonary artery hypertension4.4. Heart failure; 4.5. Cardiomyopathies; 4.5.1. Dilated cardiomyopathy; 4.5.2. Hypertrophic cardiomyopathy; 4.5.3. Other cardiomyopathies; 4.6. Arrhythmias; 4.7. Cardiotoxicity induced by anticancer therapy; 4.7.1. Diagnostic methods; 4.7.2. Cardiac troponins; 5. Biologic Variability; 6. Conclusion; Acknowledgments; References; Chapter Three: Markers in Nonalcoholic Steatohepatitis; 1. Introduction; 2. Epidemiology and Associated Conditions; 3. Pathogenesis and Histological Features; 4. Clinical and Diagnostic Approach; 5. Liver Function Tests.

6. Adipokines, Endocrine Mediators, and Signaling Networks in NASH7. Cytokines and Inflammation Biomarkers; 8. Oxidative Stress Markers; 9. Noninvasive Serum Biomarkers of Fibrosis; 9.1. Indirect markers of fibrosis; 9.2. Direct markers of fibrosis; 9.2.1. Markers associated with matrix deposition; 9.2.2. Markers associated with matrix degradation; 9.3. Cytokines and other markers associated with hepatic fibrosis; 9.4. Diagnostic panels to assess NASH; 10. Potential Genetic Modifiers and Novel Markers; 11. Conclusion; References.

Chapter Four: The Expanding Role of Tandem Mass Spectrometry in Optimizing Diagnosis and Treatment of Thyroid Disease.

Volume 61 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology. Written by authors representing the diverse field of clinical chemistry and diagnostics, reviews in Advances in Clinical Chemistry cover a range of cutting-edge research ranging from basic biochemical exploration to microarray technolog.

Includes index.

Description based on print version record.